Zanubrutinib in Waldenström macroglobulinemia: Considerations for Treatment-Naïve vs Relapsed Patients
Waldenström macroglobulinemia (WM) is a rare, indolent B-cell lymphoma of lymphoplasmacytic origin characterized by bone marrow involvement and can produce excess amounts of IgM proteins that cause symptoms and complications in affected patients. In the last few years, WM treatment has evolved with the introduction of novel targeted therapies. Among these, BTK inhibitors have been found […]









